CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishA inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-PLC signaling activity, its downstream effects and its role in haematological malignancies. PI-PLC β1 is involved in the physiological control of the cell cycle and by acting on the Cylin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. In hematological malignancies recent studies showed that PI-PLC β1 mono-allelic deletion correlates with a higher risk of AML evolution. Moreover it has been shown that PI-PLC β1 promoter is hypermethylated in high-risk MDS patients and that the amount of PI-PLC β1 mRNA could predict the clinical response to azacitidine, a well known demethylating drug. All in all the data reviewed here pave the way to a new prognostic and therapeutic strategy in some haematological malignancies.
| Titolo: | Inositide signaling in the nucleus: From physiology to pathology. | |
| Autore/i: | COCCO, LUCIO ILDEBRANDO; FOLLO, MATILDE YUNG; FAENZA, IRENE; BILLI, ANNA MARIA; RAMAZZOTTI, GIULIA; MARTELLI, ALBERTO MARIA; MANZOLI, LUCIA; Weber G. | |
| Autore/i Unibo: | ||
| Anno: | 2010 | |
| Titolo del libro: | Advances in Enzyme Regulation | |
| Pagina iniziale: | 2 | |
| Pagina finale: | 11 | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.advenzreg.2009.10.007 | |
| Abstract: | A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-PLC signaling activity, its downstream effects and its role in haematological malignancies. PI-PLC β1 is involved in the physiological control of the cell cycle and by acting on the Cylin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. In hematological malignancies recent studies showed that PI-PLC β1 mono-allelic deletion correlates with a higher risk of AML evolution. Moreover it has been shown that PI-PLC β1 promoter is hypermethylated in high-risk MDS patients and that the amount of PI-PLC β1 mRNA could predict the clinical response to azacitidine, a well known demethylating drug. All in all the data reviewed here pave the way to a new prognostic and therapeutic strategy in some haematological malignancies. | |
| Data prodotto definitivo in UGOV: | 23-feb-2011 | |
| Data stato definitivo: | 27-lug-2017 | |
| Appare nelle tipologie: | 2.01 Capitolo / saggio in libro |
File in questo prodotto:
Copyright © 2021